Biota Pharmaceuticals Inc Stock Nasdaq
Equities
US6295191091
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Mar. 14 | Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 14 | Transcript : Vaxart, Inc., 2023 Earnings Call, Mar 14, 2024 |
Financials (USD)
Sales 2024 * | 14.73M | Sales 2025 * | 23.1M | Capitalization | 146M |
---|---|---|---|---|---|
Net income 2024 * | -77M | Net income 2025 * | -80M | EV / Sales 2024 * | 9.94 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 6.34 x |
P/E ratio 2024 * |
-1.86
x | P/E ratio 2025 * |
-2.14
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.75% |
Latest transcript on Biota Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Sean Tucker
FOU | Founder | - | 03-12-31 |
Phillip Eric Lee
DFI | Director of Finance/CFO | 37 | 22-12-18 |
Michael Finney
CHM | Chairman | 65 | 07-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Yedid
BRD | Director/Board Member | 66 | 19-10-24 |
Elaine Heron
BRD | Director/Board Member | 76 | 22-08-24 |
Michael Finney
CHM | Chairman | 65 | 07-06-30 |
1st Jan change | Capi. | |
---|---|---|
-3.30% | 102B | |
+1.79% | 96.84B | |
-0.44% | 21.48B | |
-18.35% | 20.82B | |
-7.45% | 18.6B | |
-40.31% | 16.81B | |
-26.84% | 13.78B | |
+0.59% | 13.4B | |
+20.86% | 11.06B |